Chen, F, et al., The Effects of Simvastatin Treatment on Plasma Lipid-Related Biomarkers in Men with Dyslipidaemia. Biomarkers, 2011. 16(4): 321-333.
Lipidomic biomarkers will facilitate the development of novel anti-atherosclerotic therapies.
To evaluate the responses of circulating biomarkers to simvastatin treatment.
A randomized, cross-over study in men with mixed dyslipidaemia was used to compare effects of simvastatin 40 mg/day with placebo.
Plasma concentrations of nine fatty acids (FA; of 33 evaluated) were reduced significantly by simvastatin. No changes in the rates of FA synthesis or in hepatic lipase or lipoprotein lipase activities were apparent. Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) levels increased.
We identified lipidomic biomarkers of simvastatin treatment effect that are consistent with statin inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase (ClinicalTrials.gov: NCT00935259).